Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Topline results were announced from a phase 3 trial evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as a flexible-dose monotherapy for the treatment of early Parkinson ...

AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...

US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a ...